Fulcrum Therapeutics (FULC) Equity Average (2019 - 2025)
Historic Equity Average for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $206.4 million.
- Fulcrum Therapeutics' Equity Average fell 2228.23% to $206.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.4 million, marking a year-over-year decrease of 2228.23%. This contributed to the annual value of $239.1 million for FY2024, which is 1015.63% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Equity Average stood at $206.4 million, which was down 2228.23% from $221.4 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Equity Average ranged from a high of $285.8 million in Q2 2023 and a low of $111.5 million during Q1 2021
- In the last 5 years, Fulcrum Therapeutics' Equity Average had a median value of $221.4 million in 2025 and averaged $215.3 million.
- Per our database at Business Quant, Fulcrum Therapeutics' Equity Average surged by 12089.07% in 2021 and then plummeted by 2228.23% in 2025.
- Fulcrum Therapeutics' Equity Average (Quarter) stood at $221.1 million in 2021, then dropped by 4.93% to $210.2 million in 2022, then rose by 16.72% to $245.3 million in 2023, then rose by 1.97% to $250.2 million in 2024, then fell by 17.5% to $206.4 million in 2025.
- Its Equity Average stands at $206.4 million for Q3 2025, versus $221.4 million for Q2 2025 and $235.8 million for Q1 2025.